NEWS & MEDIA

NEOVACS TO COLLABORATE WITH THE SUNNYBROOK RESEARCH INSTITUTE FOR PRECLINICAL DEVELOPMENT OF VEGF KINOID

Paris and Boston, January 5th, 2017 – Neovacs (Alternext Paris: ALNEV)

 

 

Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs’ VEGF Kinoid, specifically to obtain the proof of concept for the treatment of colorectal and ovarian cancer.

Download the pdf